Company news

Disc Medicine, Inc. (NASDAQ:IRON) news

Disc Medicine, Inc. news releases on 6ix. Latest, Aug 31, 2026: Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic…

Disc Medicine, Inc. (NASDAQ:IRON) news

Press releases & updates

Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis and Anemia at the 2026 American Society of Clinical Oncology Annual Meeting

Disc Medicine : Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria

Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Disc Medicine : Bitopertin Regulatory Update

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

Disc Medicine : 2025 ASH Management Call FINAL

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update

OrbiMed Promotes Mona Ashiya to General Partner

Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025

Disc Medicine Appoints Nadim Ahmed to its Board of Directors

Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting